

Erratum: Randomized, blinded trial of vitamin D₃ for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS)

Alice C. Shapiro¹ · Susan A. Adlis¹ · Kim Robien³ · Mark N. Kirstein⁴ ·
Shuang Liang^{4,5} · Sara A. Richter¹ · Rachel E. Lerner²

Published online: 11 May 2016
© Springer Science+Business Media New York 2016

Erratum to: Breast Cancer Res Treat (2016)
155:501–512
DOI 10.1007/s10549-016-3710-6

was 500 mg/day for the study period of 7 month (includes the 1 month run-in period). The authors apologize for this error.

In the original publication of the article, the calcium carbonate supplement was published incorrectly. The correct amount of calcium carbonate taken by all study participants

The online version of the original article can be found under
doi:[10.1007/s10549-016-3710-6](https://doi.org/10.1007/s10549-016-3710-6).

✉ Alice C. Shapiro
alice.shapiro@parknicollet.com

- ¹ Oncology Research, Park Nicollet Institute and Frauenshuh Cancer Center, 3932 Louisiana Avenue S., Minneapolis, MN 55416, USA
- ² Park Nicollet Frauenshuh Cancer Center, Minneapolis, MN, USA
- ³ Milken Institute School of Public Health, George Washington University, Washington, DC, USA
- ⁴ University of Minnesota College of Pharmacy, Minneapolis, MN, USA
- ⁵ University of Minnesota School of Public Health, Minneapolis, MN, USA